4 ms·

To be clear these side-effects are likely caused by the host immunological response to the SARS-CoV-2 virus, as opposed to "bad" or contaminated vaccines. One

To be clear these side-effects are likely caused by the host immunological response to the SARS-CoV-2 virus, as opposed to "bad" or contaminated vaccines. One reason children may be more prone to side effects such as heart inflammation is because they are likely to already have naturally acquired immunity, thus the immune response induced by a highly effective vaccine may be 'overwhelming' [5]. > More than half of the cases reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) after people had received their second dose of either the Pfizer/BioNTech or Moderna vaccines were in people between the ages of 12 and 24, the CDC said. Those age groups accounted for less than 9% of doses administered. [1] > In this small case series study, myocarditis was diagnosed in 15 children after COVID-19 vaccination, most commonly in boys after the second dose. In this case series, in short-term follow-up, patients were mildly affected. The long-term risks associated with postvaccination myocarditis remain unknown. [2] > Acute myocarditis with intense systemic inflammation and atypical Kawasaki disease is an emerging severe pediatric disease following SARS-CoV-2 infection. A delayed and inappropriate host immunological response is suspected. [3] > It should be appreciated that myocardial inflammation alone by macrophages and T cells can be seen in noninfectious deaths and COVID-19 cases, but the extent of each is different, and in neither case do such findings represent clinically relevant myocarditis. [4] [1] https://www.reuters.com/world/us/cdc-heart-inflammation-cases-ages-16-24-higher-than-expected-after-mrna-covid-19-2021-06-10/ https://www.reuters.com/world/us/cdc-heart-inflammation-case... [2] Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052 https://jamanetwork.com/journals/jamacardiology/fullarticle/... [3] Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-020-00690-8 https://annalsofintensivecare.springeropen.com/articles/10.1... [4] Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816957/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816957/ [5] Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 https://www.nature.com/articles/s41591-021-01325-6 https://www.nature.com/articles/s41591-021-01325-6

galangalalgol 5y ago
I wonder if there was some part of COVID-19 besides the spike protein we could have used that would have resulted in fewer problems.
- orra 5y ago
  IMHO, the targetting the spike protein helps the vaccines remain highly effective against variants. SARS-CoV-2 can evolve, but without the spike it wouldn't be so infectious (and with the spike, the vaccines already target it).
chana_masala 5y ago
> children ... are likely to already have naturally acquired immunity Can you explain how you have come to that understanding? And further, why are children not dying at the same rate as adults with covid?
- onlyrealcuzzo 5y ago
  The older you are, the more likely Covid is to kill you [1]. > Compared with 18- to 29-year-olds, the rate of death is four times higher in 30- to 39-year-olds, and 600 times higher in those who are 85 years and older. (In the table, a rate of 1x indicates no difference compared to the 18- to 29-year-old age category.) [1] https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investi...
  - criticaltinker 5y ago
    Yes, data shows that the infection fatality rate is very low for children. Adding to that, evidence suggests that the vast majority (65% - 95%) of infections in children are asymptomatic [1]. Overall this implies that many children have or will obtain naturally acquired immunity. [1] Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of nationwide serosurvey data in the Netherlands https://link.springer.com/article/10.1007/s10654-021-00768-y https://link.springer.com/article/10.1007/s10654-021-00768-y

galangalalgol 5y ago

I wonder if there was some part of COVID-19 besides the spike protein we could have used that would have resulted in fewer problems.

orra 5y ago
IMHO, the targetting the spike protein helps the vaccines remain highly effective against variants. SARS-CoV-2 can evolve, but without the spike it wouldn't be so infectious (and with the spike, the vaccines already target it).

chana_masala 5y ago

> children ... are likely to already have naturally acquired immunity Can you explain how you have come to that understanding? And further, why are children not dying at the same rate as adults with covid?

onlyrealcuzzo 5y ago
The older you are, the more likely Covid is to kill you [1]. > Compared with 18- to 29-year-olds, the rate of death is four times higher in 30- to 39-year-olds, and 600 times higher in those who are 85 years and older. (In the table, a rate of 1x indicates no difference compared to the 18- to 29-year-old age category.) [1] https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investi...
- criticaltinker 5y ago
  Yes, data shows that the infection fatality rate is very low for children. Adding to that, evidence suggests that the vast majority (65% - 95%) of infections in children are asymptomatic [1]. Overall this implies that many children have or will obtain naturally acquired immunity. [1] Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of nationwide serosurvey data in the Netherlands https://link.springer.com/article/10.1007/s10654-021-00768-y https://link.springer.com/article/10.1007/s10654-021-00768-y